NF-LIGHT®: Ultra-Sensitive NFL Assay for Neurology Research
NF-LIGHT®, our Nfl assay, is an immunoassay kit for the ultra-sensitive measurement of neurofilament light levels in serum, plasma and…
Posted on
PLOS ONE
Wallace C, Zetterberg H, Blennow K and van Donkelaar P.
PLoS One. 2018 Oct 29;13(10):e0206466.
DOI: 10.1371/journal.pone.0206466
This study was peformed using a Simoa® Homebrew assay.
Sport-related concussion (SRC), a mild form of traumatic brain injury (TBI), is a common injury in contact sports. Health care professionals rely on subjective criteria (e.g., symptoms), as there is no objective marker for identification of athletes with SRC. Blood-based biomarkers have shown promise as diagnostic and prognostic tools following TBI and SRC. In the present study, we examined plasma tau and serumNF-L, two biomarkers for neuronal/axonal injury, concentrations at preseason and following SRC in contact sport athletes (n = 11) using ultrasensitive single molecule array (Simoa) assays. Preseason baseline samples were collected, and post-concussion samples were obtained at 6- and 14-days following injury. We found no difference between baseline, 6-day and 14-day post-concussion concentrations of tau (p = 0.14) or NF-L (p = 0.53). Further, no difference was found between preseason baseline and all post-SRC samples for tau (p = 0.22) or NF-L (p = 0.98). The total number of symptoms reported on the Standardized Assessment of Concussion- 3rd Edition (SCAT3) and associated symptom severity scores increased from preseason to 6-days post-SRC but returned to baseline values at 14-days (p = 0.02 and p = 0.003, respectively). These results suggest that the severity of neuronal injury in this cohort of contact sport athletes with clinical uncomplicated SRC was too low to be detected by tau and NF-L measurements in blood samples obtained at 6- and 14-days post-injury.
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
NF-LIGHT®, our Nfl assay, is an immunoassay kit for the ultra-sensitive measurement of neurofilament light levels in serum, plasma and…
Our SIMOA® Tau Kit is designed for the measurement of Tau in serum, human plasma and CSF. Click here to…